In today’s recent session, 3.26 million shares of the Salarius Pharmaceuticals Inc (NASDAQ:SLRX) have been traded, and its beta is 1.02. Most recently the company’s share price was $2.29, and it changed around $0.43 or 23.12% from the last close, which brings the market valuation of the company to $1.37M. SLRX at last check was trading at a discount to its 52-week high of $7.90, offering almost -244.98% off that amount. The share price’s 52-week low was $1.35, which indicates that the recent value has risen by an impressive 41.05% since then. We note from Salarius Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 4.38 million shares, with the 3-month average coming to 2.09 million.
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) trade information
Instantly SLRX has been showing a green trend so far today with a performance of 23.12% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.7299 on recent trading dayincreased the stock’s daily price by 16.11%. The company’s shares are currently down -55.96% year-to-date, but still down -10.55% over the last five days. On the other hand, Salarius Pharmaceuticals Inc (NASDAQ:SLRX) is -16.12% down in the 30-day period. We can see from the shorts that 59939.0 shares have been sold at a short interest cover period of 0.33 day(s).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Salarius Pharmaceuticals Inc (SLRX) estimates and forecasts
Salarius Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -48.87 percent over the past six months and at a -597.92% annual growth rate that is well below the industry average of 14.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -200.40% in revenue this quarter, and will report a decrease of -368.50% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 64.97%.
SLRX Dividends
Salarius Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Aug-08.
Salarius Pharmaceuticals Inc (NASDAQ:SLRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.08% of Salarius Pharmaceuticals Inc shares, and 4.03% of them are in the hands of institutional investors. The stock currently has a share float of 4.29%.
